This document discusses trends in antibody and biologic drug development and proposes a platform approach for suppliers to better support customers' product life cycles. It notes that 75% of drug pipelines are in early stages and that antibody formats are diversifying beyond monoclonal antibodies. This diversification and the need for flexibility, standardization, and multi-product facilities is driving a shift toward platform approaches using single-use and continuous manufacturing. The document advocates that suppliers provide consistent support through a product's entire life cycle via integrated platforms that facilitate technology transfer and operations. It argues that a well-designed platform can have benefits greater than the individual parts by enhancing flexibility, predictability and the ability to adapt processes to industrial-scale manufacturing.